Seres Selling General Administrative vs Net Income From Continuing Ops Analysis

MCRB Stock

USD 0.73 0.08 9.65%

Seres Therapeutics financial indicator trend analysis is much more than just breaking down Seres Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Seres Therapeutics is a good investment. Please check the relationship between Seres Therapeutics Selling General Administrative and its Net Income From Continuing Ops accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Selling General Administrative vs Net Income From Continuing Ops

Selling General Administrative vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Seres Therapeutics Selling General Administrative account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have pay attention.

The correlation between Seres Therapeutics' Selling General Administrative and Net Income From Continuing Ops is -0.84. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Seres Therapeutics, assuming nothing else is changed. The correlation between historical values of Seres Therapeutics' Selling General Administrative and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Seres Therapeutics are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Selling General Administrative i.e., Seres Therapeutics' Selling General Administrative and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.84

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Selling General Administrative

Net Income From Continuing Ops

Most indicators from Seres Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Seres Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.The current year's Selling General Administrative is expected to grow to about 92.1 M, whereas Issuance Of Capital Stock is forecasted to decline to about 12.3 M.

	2023	2024 (projected)
Non Recurring	1.3M	1.2M
Reconciled Depreciation	6.2M	5.5M

Non Recurring Reconciled Depreciation

Seres Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Property Plant And Equipment Gross
Total Assets		0.67	0.79	0.42	0.65	-0.06	-0.77	0.74	0.85	0.71	0.47	0.66	0.9	0.75	0.49	0.73	0.94	0.82	0.59	0.7	0.49	0.54	0.8	0.68	0.76	0.59
Other Current Liab	0.67		0.88	-0.18	0.95	0.49	-0.9	0.64	0.68	0.91	0.74	0.51	0.4	0.91	0.36	0.87	0.46	0.9	0.93	0.45	0.06	0.84	0.9	0.85	0.87	0.9
Total Current Liabilities	0.79	0.88		-0.11	0.9	0.35	-0.98	0.67	0.76	0.9	0.79	0.55	0.58	0.97	0.6	0.95	0.64	0.97	0.88	0.74	0.44	0.88	0.97	0.92	0.96	0.88
Total Stockholder Equity	0.42	-0.18	-0.11		-0.27	-0.52	0.15	0.24	0.17	-0.16	-0.3	0.29	0.66	-0.14	0.01	-0.27	0.61	-0.03	-0.3	0.0	0.26	-0.36	-0.05	-0.33	-0.06	-0.31
Property Plant And Equipment Net	0.65	0.95	0.9	-0.27		0.62	-0.91	0.56	0.58	0.97	0.84	0.43	0.35	0.92	0.32	0.93	0.42	0.91	0.97	0.57	0.14	0.91	0.91	0.92	0.84	0.98
Net Debt	-0.06	0.49	0.35	-0.52	0.62		-0.4	-0.18	-0.24	0.6	0.67	0.09	-0.38	0.45	-0.11	0.41	-0.31	0.4	0.67	0.03	-0.26	0.65	0.43	0.44	0.34	0.69
Retained Earnings	-0.77	-0.9	-0.98	0.15	-0.91	-0.4		-0.62	-0.74	-0.92	-0.78	-0.63	-0.53	-0.98	-0.58	-0.95	-0.6	-0.98	-0.9	-0.72	-0.44	-0.9	-0.98	-0.92	-0.98	-0.89
Accounts Payable	0.74	0.64	0.67	0.24	0.56	-0.18	-0.62		0.75	0.5	0.19	0.24	0.71	0.56	0.54	0.58	0.71	0.62	0.41	0.64	0.36	0.31	0.6	0.52	0.6	0.43
Cash	0.85	0.68	0.76	0.17	0.58	-0.24	-0.74	0.75		0.59	0.42	0.55	0.79	0.72	0.55	0.74	0.82	0.74	0.55	0.57	0.41	0.53	0.72	0.7	0.74	0.51
Non Current Assets Total	0.71	0.91	0.9	-0.16	0.97	0.6	-0.92	0.5	0.59		0.86	0.57	0.43	0.94	0.31	0.93	0.5	0.93	0.96	0.59	0.2	0.92	0.94	0.92	0.87	0.97
Non Currrent Assets Other	0.47	0.74	0.79	-0.3	0.84	0.67	-0.78	0.19	0.42	0.86		0.38	0.23	0.85	0.19	0.82	0.31	0.78	0.92	0.34	0.07	0.94	0.81	0.82	0.74	0.92
Other Assets	0.66	0.51	0.55	0.29	0.43	0.09	-0.63	0.24	0.55	0.57	0.38		0.57	0.66	0.28	0.52	0.61	0.67	0.49	0.38	0.4	0.51	0.66	0.49	0.71	0.43
Cash And Short Term Investments	0.9	0.4	0.58	0.66	0.35	-0.38	-0.53	0.71	0.79	0.43	0.23	0.57		0.52	0.49	0.49	0.99	0.6	0.29	0.57	0.6	0.25	0.58	0.43	0.56	0.29
Common Stock Shares Outstanding	0.75	0.91	0.97	-0.14	0.92	0.45	-0.98	0.56	0.72	0.94	0.85	0.66	0.52		0.51	0.95	0.59	0.98	0.94	0.61	0.32	0.92	0.98	0.92	0.96	0.91
Other Current Assets	0.49	0.36	0.6	0.01	0.32	-0.11	-0.58	0.54	0.55	0.31	0.19	0.28	0.49	0.51		0.49	0.5	0.58	0.31	0.61	0.73	0.33	0.56	0.43	0.6	0.27
Total Liab	0.73	0.87	0.95	-0.27	0.93	0.41	-0.95	0.58	0.74	0.93	0.82	0.52	0.49	0.95	0.49		0.55	0.93	0.91	0.7	0.35	0.91	0.93	0.99	0.89	0.92
Total Current Assets	0.94	0.46	0.64	0.61	0.42	-0.31	-0.6	0.71	0.82	0.5	0.31	0.61	0.99	0.59	0.5	0.55		0.67	0.37	0.61	0.59	0.34	0.65	0.49	0.62	0.37
Common Stock	0.82	0.9	0.97	-0.03	0.91	0.4	-0.98	0.62	0.74	0.93	0.78	0.67	0.6	0.98	0.58	0.93	0.67		0.91	0.67	0.45	0.89	1.0	0.89	0.97	0.89
Short Long Term Debt Total	0.59	0.93	0.88	-0.3	0.97	0.67	-0.9	0.41	0.55	0.96	0.92	0.49	0.29	0.94	0.31	0.91	0.37	0.91		0.44	0.11	0.97	0.92	0.91	0.86	0.99
Other Liab	0.7	0.45	0.74	0.0	0.57	0.03	-0.72	0.64	0.57	0.59	0.34	0.38	0.57	0.61	0.61	0.7	0.61	0.67	0.44		0.71	0.49	0.66	0.65	0.67	0.51
Current Deferred Revenue	0.49	0.06	0.44	0.26	0.14	-0.26	-0.44	0.36	0.41	0.2	0.07	0.4	0.6	0.32	0.73	0.35	0.59	0.45	0.11	0.71		0.22	0.43	0.29	0.46	0.12
Long Term Debt	0.54	0.84	0.88	-0.36	0.91	0.65	-0.9	0.31	0.53	0.92	0.94	0.51	0.25	0.92	0.33	0.91	0.34	0.89	0.97	0.49	0.22		0.91	0.91	0.87	0.96
Common Stock Total Equity	0.8	0.9	0.97	-0.05	0.91	0.43	-0.98	0.6	0.72	0.94	0.81	0.66	0.58	0.98	0.56	0.93	0.65	1.0	0.92	0.66	0.43	0.91		0.9	0.97	0.9
Non Current Liabilities Total	0.68	0.85	0.92	-0.33	0.92	0.44	-0.92	0.52	0.7	0.92	0.82	0.49	0.43	0.92	0.43	0.99	0.49	0.89	0.91	0.65	0.29	0.91	0.9		0.84	0.92
Other Stockholder Equity	0.76	0.87	0.96	-0.06	0.84	0.34	-0.98	0.6	0.74	0.87	0.74	0.71	0.56	0.96	0.6	0.89	0.62	0.97	0.86	0.67	0.46	0.87	0.97	0.84		0.82
Property Plant And Equipment Gross	0.59	0.9	0.88	-0.31	0.98	0.69	-0.89	0.43	0.51	0.97	0.92	0.43	0.29	0.91	0.27	0.92	0.37	0.89	0.99	0.51	0.12	0.96	0.9	0.92	0.82

Click cells to compare fundamentals

Seres Therapeutics Account Relationship Matchups

Seres Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	132.4M	342.9M	354.9M	348.8M	358.6M	225.8M
Other Current Liab	10.9M	21.7M	38.5M	105.0M	73.9M	77.6M
Total Current Liabilities	46.0M	46.4M	82.3M	85.6M	98.7M	103.6M
Total Stockholder Equity	(48.3M)	174.8M	131.5M	10.8M	(44.9M)	(42.6M)
Property Plant And Equipment Net	30.9M	22.9M	36.1M	134.0M	132.3M	138.9M
Net Debt	(20.3M)	(75.3M)	(130.8M)	(440K)	86.0M	90.3M
Retained Earnings	(459.6M)	(548.8M)	(614.4M)	(864.5M)	(978.2M)	(929.3M)
Accounts Payable	4.9M	4.0M	13.7M	17.4M	3.6M	6.7M
Cash	65.1M	116.0M	180.0M	163.0M	128.0M	93.9M
Non Current Assets Total	32.3M	74.2M	51.2M	154.0M	183.2M	192.3M
Cash And Short Term Investments	94.8M	253.6M	290.7M	181.3M	128.0M	156.3M
Common Stock Shares Outstanding	56.6M	79.8M	91.7M	108.1M	128.0M	134.4M
Other Current Assets	33.3M	11.5M	25.8M	13.4M	9.1M	10.4M
Total Liab	180.8M	168.2M	223.4M	338.0M	403.5M	423.6M
Total Current Assets	100.2M	268.8M	303.6M	194.8M	175.4M	166.7M
Common Stock	70K	91K	92K	125K	135K	141.8K
Short Long Term Debt Total	44.8M	40.8M	49.2M	162.6M	213.9M	224.6M
Other Liab	94.4M	86.6M	98.5M	93.9M	108.0M	78.0M
Current Deferred Revenue	25.8M	22.6M	16.8M	4.3M	7.7M	13.6M
Common Stock Total Equity	70K	91K	92K	125K	143.8K	150.9K
Liabilities And Stockholders Equity	132.4M	342.9M	354.9M	348.8M	358.6M	245.7M
Non Current Liabilities Total	134.8M	121.8M	141.1M	252.4M	304.8M	320.0M
Other Stockholder Equity	411.3M	723.5M	745.8M	875.2M	933.2M	979.9M
Property Plant And Equipment Gross	30.9M	22.9M	36.1M	134.0M	183.4M	192.6M
Accumulated Other Comprehensive Income	(27.7M)	(47K)	(60K)	(12K)	(13.8K)	(14.5K)
Short Term Debt	4.5M	5.6M	13.2M	4.1M	13.4M	7.8M
Property Plant Equipment	19.5M	13.9M	36.1M	23.0M	26.4M	21.7M
Net Tangible Assets	(48.3M)	174.8M	131.5M	10.8M	9.7M	9.2M
Short Term Investments	113.9M	0.0	29.7M	137.6M	110.7M	18.3M
Retained Earnings Total Equity	(459.6M)	(548.8M)	(614.4M)	(864.5M)	(778.1M)	(739.2M)
Capital Surpluse	411.3M	723.5M	745.8M	875.2M	1.0B	552.2M
Non Current Liabilities Other	110.1M	97.1M	116.5M	201.8M	1.6M	1.5M
Capital Lease Obligations	20.1M	15.7M	24.6M	111.5M	112.4M	118.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:

How To Invest In Seres

Details

Is Seres Stock a good investment?

Details

What is Seres Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.40)

Revenue Per Share

0.871

Quarterly Revenue Growth

(0.93)

Return On Assets

(0.1)

Return On Equity

(15.56)

The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Seres Selling General Administrative vs Net Income From Continuing Ops Analysis

Selling General Administrative vs Net Income From Continuing Ops

Selling General Administrative vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Selling General Administrative

Net Income From Continuing Ops

Seres Therapeutics fundamental ratios Correlations

Seres Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Seres Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Common Stock
Total Current Assets	+ 0.99	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.99	Total Liab
Property Plant And Equipment Gross	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Common Stock	+ 0.98	Common Stock Shares Outstanding

Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.98	Retained Earnings
Common Stock	- 0.98	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Total Liab	- 0.95	Retained Earnings